Results 31 to 40 of about 424,109 (164)

Table1_Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.xlsx [PDF]

, 2023
ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and ...
Pasquale Sessa (17445048), Kristian Hay Kragholm (13174425), Francesco Sessa (2817850), Paolo Polverino (10897845), Maurizio Sessa (3146397), Manan Pareek (738565)   +5 more
core   +1 more source

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273

Microbiology Spectrum, 2022
While mRNA vaccines are highly efficacious against short-term COVID-19, long-term immunogenicity is less clear. We compared humoral immunogenicity between BNT162b2 and mRNA-1273 vaccines 6 months after the first vaccine dose, examining the wild-type ...
Brian Grunau, Liam Golding, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, Richard Armour, Ana Citlali Marquez, Agatha N. Jassem, Vilte Barakauskas, Sheila F. O’Brien, Steven J. Drews, Scott Haig, Pascal M. Lavoie, David M. Goldfarb   +12 more
doaj   +1 more source

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients [PDF]

, 2022
ImportanceIn patients with hematologic malignancies, the immunogenicity of the standard 2-dose mRNA-1273 coronavirus disease 19 (COVID-19) vaccination schedule is often insufficient due to underlying disease and current or recent therapy.
Haggenburg, S., Kater, A. P., van Gils, M. J., van Leeuwen, E. M. M., Beaumont, T., Hofsink, Q., Broers, A. E. C., van Binnendijk, R. S., Haverkate, N. J. E., Burger, J. A., Mutsaers, P. G. N. J., Smits, G. P., van Doesum, J. A., Kootstra, N. A., Heemskerk, M. H. M., Bontkes, H. J., Lissenberg-Witte, B. I., Hazenberg, M. D., Goorhuis, A., Wouters, D., van Meerten, T., Bhoekhan, M. S., Nijhof, I. S., Bouhuijs, J. H., Groen, K., den Hartog, G., Zweegman, S., Rutten, C. E.   +27 more
core   +1 more source

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

International Journal of Infectious Diseases, 2022
Background: Health care workers (HCWs), a high-risk group for contracting COVID-19 disease, are being prioritized to receive COVID-19 vaccination. A third dose messenger RNA (mRNA) vaccine, mRNA-1273 (Moderna), after 2 doses of inactivated vaccine ...
Cucunawangsih Cucunawangsih, Ratna Sari Wijaya, Nata Pratama Hardjo Lugito, Ivet Suriapranata   +3 more
doaj   +1 more source

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination [PDF]

, 2022
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC ...
Normark, Johan, Garcia, Marina,, Ackerman, Margaret E.,, Ahlm, Clas,, Johnson, Carl E.,, Ahlm, Clas, Christ, Wanda, Normark, Johan,, Walker, Laura M.,, Walker, Laura M., Klingström, Jonas, Kaku, Chengzi I.,, Champney, Elizabeth R.,, Klingström, Jonas,, Kaku, Chengzi I., Christ, Wanda,, Johnson, Carl E., Sakharkar, Mrunal, Sakharkar, Mrunal,, Forsell, Mattias N. E.,, Garcia, Marina, Ackerman, Margaret E., Forsell, Mattias N. E., Champney, Elizabeth R.   +23 more
core   +1 more source

Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection [PDF]

, 2021
The mRNA-1273 vaccine is effective against SARS-CoV-2 and was granted emergency use authorization by the FDA. Clinical studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with ...
Mire, Chad E., Chen, Xi, Periasamy, Sivakumar, Bock, Kevin W., Wang, Yuan, Troyanskaya, Olga G., Carfi, Andrea, Woods, Angela, Zaslavsky, Elena, Rubenstein, Aliza B., Pietzsch, Colette, Ramos, Irene, Shi, Pei-Yong, Ma, LingZhi, Graham, Barney S., Minai, Mahnaz, Sealfon, Stuart C., Ramanathan, Palaniappan, Meyer, Michelle, Ge, Yongchao, Cheng, Wan Sze, Edwards, Darin, Smith, Gregory R., Nagata, Bianca M., Bukreyev, Alexander, Henry, Carole, Stewart-Jones, Guillaume B.E., Moore, Ian N.   +27 more
core   +1 more source

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial [PDF]

, 2022
BACKGROUND BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent SARS-CoV-2 infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking.
Trkola, A., Eichenberger, Anna L, Günthard, Huldrych F, Speich, Benjamin, Audigé, A., Chammartin, Frédérique, Mueller, N.J., Koller, Michael T, Tamm, M., Schuurmans, Macé M, Stoeckle, M.P., Trkola, Alexandra, Amico, P., Audigé, Annette, Rauch, A., Bucher, Heiner C, Chammartin, F., Abela, I.A., Braun, Dominique L, Mueller, Nicolas J, Swiss HIV Cohort Study, Swiss Transplant Cohort Study, Amico, Patrizia, Speich, B., Hasse, Barbara, Koller, M.T., Kusejko, K., Tamm, Michael, Rauch, Andri, Müller, Thomas F, Braun, D.L., Briel, M., Günthard, H.F., Schuurmans, M.M., Stoeckle, Marcel P, Kusejko, Katharina, Hasse, B., Briel, Matthias, Bucher, H.C., Müller, T.F., Eichenberger, A.L., Abela, Irene A   +41 more
core   +1 more source

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021

Journal of the Formosan Medical Association, 2022
Background: Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality.
Kuan-Yin Lin, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang   +6 more
doaj   +1 more source

Baseline characteristics of 2-dose mRNA-1273 vaccinated and unvaccinated cohort. [PDF]

, 2022
Baseline characteristics of 2-dose mRNA-1273 vaccinated and unvaccinated cohort.
Katia J. Bruxvoort (12476079), Yun Tian (411157), Hung Fu Tseng (12476097), Ana Florea (12476073), Gina S. Lee (12476085), Jennifer H. Ku (12476088), Yi Luo (143206), Lei Qian (292302), Bradley K. Ackerson (12476082), Julia E. Tubert (12476091), Lina S. Sy (12476076), Carla A. Talarico (12476094)   +11 more
core   +1 more source

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19. [PDF]

, 2022
Importance: It has become common practice to offer immunocompromised patients with hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce.
Heemskerk, Mirjam H M, Groen, Kaz, Broers, Annoek E.C., Zweegman, Sonja, Nijhof, Inger S., Beaumont, Tim, Mutsaers, Pim G. N. J., Haggenburg, Sabine, van Binnendijk, Rob S, van Binnendijk, Rob S., Bouhuijs, Joey H., Heemskerk, Mirjam H.M., Hazenberg, Mette D., Wouters, Dorine, van Leeuwen, Ester M. M., Rutten, Caroline E., Haverkate, Nienke J.E., Bhoekhan, Michel S, van Doesum, Jaap A., van Meerten, Tom, Nijhof, Inger S, Haverkate, Nienke J. E., Kater, Arnon P, Hazenberg, Mette D, Smits, Gaby P, Heemskerk, Mirjam H. M., Rutten, Caroline E, Kootstra, Neeltje A, Kater, Arnon P., Kootstra, Neeltje A., Bhoekhan, Michel S., Broers, Annoek E C, Bontkes, Hetty J., Goorhuis, Abraham, Bontkes, Hetty J, van Doesum, Jaap A, Mutsaers, Pim G N J, Bouhuijs, Joey H, van Gils, Marit J., van Gils, Marit J, Broers, Annoek E. C., Mutsaers, Pim G.N.J., Lissenberg-Witte, Birgit, Van Leeuwen, Ester M.M., Burger, Judith A, Hofsink, Quincy, van Leeuwen, Ester M M, Burger, Judith A., Lissenberg-Witte, Birgit I, Smits, Gaby P., Lissenberg-Witte, Birgit I., Haverkate, Nienke J E, den Hartog, Gerco   +52 more
core   +4 more sources